| Bioactivity | Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist[1]. Dexloxiglumide, the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8)[2]. | ||||||||||||
| Name | Dexloxiglumide | ||||||||||||
| CAS | 119817-90-2 | ||||||||||||
| Formula | C21H30Cl2N2O5 | ||||||||||||
| Molar Mass | 461.38 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Scarpignato C, et al. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9. [2]. Maselli MA, et al. CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications. Minerva Gastroenterol Dietol. 2003 Sep;49(3):211-6. |
Dexloxiglumide
CAS: 119817-90-2 F: C21H30Cl2N2O5 W: 461.38
Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide, the active enantiomer o
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.